Clinical Trials

20 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Trastuzumab × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Parathyroid Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Somatostatinoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Gastrinoma, Pleural Effusion, Malignant, Endometrial Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Meningeal Carcinomatosis, Inflammatory Breast Neoplasms, Thyroid Carcinoma, Anaplastic